Clinical Trials Logo

Clinical Trial Summary

This study will treat patients with non-Hodgkin B-cell lymphoma who have relapsed from, refractory or intolerant to prior therapy. This study will help understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.


Clinical Trial Description

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Non-Hodgkin B-cell Lymphoma. This study includes dose escalation (Part A) and dose expansion (Part B). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04148742
Study type Interventional
Source Dizal Pharmaceuticals
Contact
Status Suspended
Phase Phase 1/Phase 2
Start date August 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04317885 - A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects Phase 1
Active, not recruiting NCT04696432 - A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma Phase 1
Terminated NCT02361346 - Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL Phase 1/Phase 2
Active, not recruiting NCT04693676 - A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04655677 - A Study of EXP039 Treatment in Subjects With r/r NHL Subjects Phase 1
Active, not recruiting NCT03000192 - HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
No longer available NCT02715843 - Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma